Bioinformatician - Single Cell Epigenomics and Cancer Development lab

Updated: about 2 months ago
Job Type: FullTime
Deadline: 08 Nov 2021

The Institute

The Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, based in Barcelona, Spain, with more than 400 scientists from 44 countries. The CRG is composed by an interdisciplinary, motivated and creative scientific team which is supported both by a flexible and efficient administration and by high-end and innovative technologies.

In April 2021, the Centre for Genomic Regulation (CRG) received the renewal of the 'HR Excellence in Research ' Award from the European Commission. This is a recognition of the Institute's commitment to developing an HR Strategy for Researchers, designed to bring the practices and procedures in line with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers (Charter and Code).

Please, check out our Recruitment Policy

The role

We are looking for an enthusiastic and motivated bioinformatician to join the Single Cell Epigenomics and Cancer Development team to provide support in creating a better understanding of early tumor formation. The candidate will lead the data analysis of different single-cell technology and 3D chromatin organisation-based projects and will provide bioinformatic support to other team members in the lab, both at the level of experimental design and data analysis. The selected candidate will also be responsible for keeping our system to store sequencing data up to date.

The layers that we aim to address in the lab at the single-cell level comprise gene expression, chromatin accessibility, DNA methylation and somatic mutations. At the level of 3D chromatin organisation, we will focus on HiC and Capture HiC data and variant calling to study allele specific effects.

About the lab

Tumors originate from normal cells that acquire tumor-initiating genetic events, such as translocations and somatic mutations. These genetic hits turn normal cells into pre-malignant cells, but do not lead to immediate tumor formation. For that, secondary genetic events as well as epigenetic hits are required.

We aim to create a better understanding of how epigenetic tumor-associated changes arise in the context of non-Hodgkin lymphomas. To that end, we aim to study the occurrence of these changes in healthy individuals as well as in pre-malignant cells in vitro (to be created by CRISPR/Cas9 genomic editing) and in vivo using single-cell technologies. On top of that, we aim to define cell intrinsic mechanisms, such as enhancer activation and 3D chromatin interactions, that influence the occurrence of the observed changes.

We are affiliated to the Gene Regulation, Stem Cell and Cancer Research program of the CRG in double affiliation with the Centre for Genomic Analysis (CNAG-CRG) and the department of Oncology and Haematology of the IDIBAPS. We strongly believe that bringing the knowledge and resources of these different environments together majorly aids to better understand the biology of disease. Further information can be found at:

View or Apply

Similar Positions